FesariusTherapeutics
United States, NY, New York
About FesariusTherapeutics
FesariusTherapeutics is a New York-based, commercial-stage medical technology company focused on dermal repair and deep wound care. Its flagship product, DermiSphere, is a hydrogel Dermal Regeneration Template (hDRT) with a patented dual-density collagen microarchitecture designed to speed cellular integration and vascularization during wound healing. The device received FDA 510(k) clearance in 2025 and is in commercial use across multiple U.S. hospital systems.
Latest Funding
Series AAnnounced 2026-06-10
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
4 signals · where the capital is going
Hiring additional direct field representatives to expand national commercial coverage.
prnewswire.com
Pursuing FDA Breakthrough Device Designation with expanded reimbursement pathways for DermiSphere.
prnewswire.com
+2 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to FesariusTherapeutics? You're in the right place.
Knowing they raised is the start. The edge is what's attached to FesariusTherapeutics.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of FesariusTherapeutics, and who are their main competitors?
Sign up free to ask AI about FesariusTherapeutics
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Johnson & Johnson Innovation – JJDC, Inc.
Lead investor · Series A
Tech Stack
HTTP/3
Google Hosted Libraries
Google Font API
Contacts
Sarah M.
Head of Sales
Sample preview. Sign up free to see real contacts
Key Highlights
AI InsightsThe $20M Series A was oversubscribed and marks the company's inaugural institutional financing round.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to FesariusTherapeutics
Selling to FesariusTherapeutics? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to FesariusTherapeutics.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.